Hikma Pharmaceuticals has doubled the size of its US business by acquiring Baxter Healthcare’s Multi-Source Injectables (MSI) business for a transaction price of US$112 M. This strategic deal will make Hikma the second largest injectables supplier by volume in the US, behind Hospira.